Novartis Prostate-Cancer Treatment Gets Positive Quality of Life Data
17 Setembro 2021 - 02:53AM
Dow Jones News
By Ed Frankl
Novartis said Friday that its prostate-cancer treatment
177Lu-PSMA-617 produced positive quality-of-life results in a Phase
3 study.
The treatment is an investigational targeted radioligand therapy
to treat metastatic castration-resistant prostate cancer, Novartis
said.
The Swiss pharmaceutical company said the Phase 3 Vision data
showed delayed worsening of symptoms with 177Lu-PSMA-617 plus
standard of care, compared to standard of care alone.
"These new data emphasize the potential impact on quality of
life that investigational 177Lu-PSMA-617 may provide as a potential
new treatment option," said Jeff Legos, global head of oncology
development at Novartis.
The company in June received FDA breakthrough therapy
designation for 177Lu-PSMA-617 in patients with prostate
cancer.
Write to Ed Frankl at edward.frankl@dowjones.com
(END) Dow Jones Newswires
September 17, 2021 01:38 ET (05:38 GMT)
Copyright (c) 2021 Dow Jones & Company, Inc.
Novartis (NYSE:NVS)
Gráfico Histórico do Ativo
De Fev 2024 até Mar 2024
Novartis (NYSE:NVS)
Gráfico Histórico do Ativo
De Mar 2023 até Mar 2024